Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new?
In recent years, highly effective target drugs – inhibitors of interleukin 17A (iIL17A) – monoclonal antibodies, – have been widely used to treat patients with psoriatic arthritis (PsA). The efficacy of iIL-17A in psoriasis, PsA, and axial spondyloarthritis has been proven in large multicenter rando...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2021-04-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1130 |
| _version_ | 1797876664076599296 |
|---|---|
| author | Т. V. Korotaeva |
| author_facet | Т. V. Korotaeva |
| author_sort | Т. V. Korotaeva |
| collection | DOAJ |
| description | In recent years, highly effective target drugs – inhibitors of interleukin 17A (iIL17A) – monoclonal antibodies, – have been widely used to treat patients with psoriatic arthritis (PsA). The efficacy of iIL-17A in psoriasis, PsA, and axial spondyloarthritis has been proven in large multicenter randomized clinical and observational studies. The accumulated evidence and first direct comparative studies with inhibitors of tumor necrosis factor α (iTNFα) suggest that this class of drugs is becoming one of the key drugs in PsA, and the choice of this therapy is more justified, which is reflected in international recommendations. The 2019 revised EULAR guidelines consider iIL 17 first-line biologics along with iTNF-α, whereas iIL-17A is a drug of choice in patients with significant concomitant skin psoriasis. |
| first_indexed | 2024-04-10T02:06:18Z |
| format | Article |
| id | doaj.art-5c4aaddb805446c48ef5915b203f37de |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2024-04-10T02:06:18Z |
| publishDate | 2021-04-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-5c4aaddb805446c48ef5915b203f37de2023-03-13T08:39:28ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2021-04-0115210611110.14412/1996-7012-2021-2-106-1112351Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new?Т. V. Korotaeva0ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»In recent years, highly effective target drugs – inhibitors of interleukin 17A (iIL17A) – monoclonal antibodies, – have been widely used to treat patients with psoriatic arthritis (PsA). The efficacy of iIL-17A in psoriasis, PsA, and axial spondyloarthritis has been proven in large multicenter randomized clinical and observational studies. The accumulated evidence and first direct comparative studies with inhibitors of tumor necrosis factor α (iTNFα) suggest that this class of drugs is becoming one of the key drugs in PsA, and the choice of this therapy is more justified, which is reflected in international recommendations. The 2019 revised EULAR guidelines consider iIL 17 first-line biologics along with iTNF-α, whereas iIL-17A is a drug of choice in patients with significant concomitant skin psoriasis.https://mrj.ima-press.net/mrj/article/view/1130псориатический артритингибиторы интерлейкина 17секукинумабиксекизумабнетакимабгенно-инженерные биологические препараты |
| spellingShingle | Т. V. Korotaeva Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new? Современная ревматология псориатический артрит ингибиторы интерлейкина 17 секукинумаб иксекизумаб нетакимаб генно-инженерные биологические препараты |
| title | Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new? |
| title_full | Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new? |
| title_fullStr | Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new? |
| title_full_unstemmed | Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new? |
| title_short | Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new? |
| title_sort | inhibitors of interleukin 17a in the treatment of psoriatic arthritis what s new |
| topic | псориатический артрит ингибиторы интерлейкина 17 секукинумаб иксекизумаб нетакимаб генно-инженерные биологические препараты |
| url | https://mrj.ima-press.net/mrj/article/view/1130 |
| work_keys_str_mv | AT tvkorotaeva inhibitorsofinterleukin17ainthetreatmentofpsoriaticarthritiswhatsnew |